Security
Harrow Inc. 8.625% Senior Notes due 2026 · HROWL
HROWLNASDAQotherHistorical · closed Oct 10, 2025CIK 1360214Updated Oct 28, 2026
Name history
HARROW HEALTH, INC. · through Sep 20, 2023Imprimis Pharmaceuticals, Inc. · through Dec 17, 2018TRANSDEL PHARMACEUTICALS INC · through Feb 27, 2012Bywater Resources, Inc · through Sep 12, 2007
Current security for this SEC filerHROW · NASDAQ
HROWL price & chart
Historical security
This listing closed Oct 10, 2025. Live provider charts are shown only for current listings.
Current security: HROW
About the company
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn (www.linkedin.com/company/harrow-health-inc/).
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Regulation FD Disclosure
Items 1.01, 2.01, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 363,074,000Source | 351,539,000Source | 416,816,000Source | 345,033,000Source | 306,630,000Source | 419,543,000Source | 364,164,000Source | 295,536,000Source | 399,482,000Source | 388,971,000Source | 312,164,000Source | 157,378,000Source |
| Property, Plant and Equipment, NetUSD | 3,380,000Source | 3,625,000Source | 2,960,000Source | 3,512,000Source | 3,288,000Source | 3,130,000Source | 3,568,000Source | 3,389,000Source | 3,260,000Source | 3,734,000Source | 3,521,000Source | 3,486,000Source |
| GoodwillUSD | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 172,457,000Source | 189,272,000Source | 175,570,000Source | 176,666,000Source | 154,884,000Source | 181,054,000Source | 180,765,000Source | 157,370,000Source | 175,174,000Source | 184,949,000Source | 159,906,000Source | 23,725,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 74,290,000Source | 72,601,000Source | 83,889,000Source | 52,963,000Source | 70,968,000Source | 94,644,000Source | 66,726,000Source | 68,538,000Source | 72,927,000Source | 47,247,000Source | 74,085,000Source | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 77,600,000Source | 53,734,000Source | 118,559,000Source | 78,822,000Source | 51,988,000Source | 101,259,000Source | 77,063,000Source | 28,960,000Source | 110,895,000Source | 116,373,000Source | 36,261,000Source | 6,249,000Source |
| Inventory, NetUSD | 12,834,000Source | 10,156,000Source | 16,910,000Source | 11,552,000Source | 9,425,000Source | 16,496,000Source | 10,716,000Source | 10,810,000Source | 13,523,000Source | 10,702,000Source | 10,867,000Source | 6,541,000Source |
| Assets, CurrentUSD | 177,604,000Source | 147,062,000Source | 229,307,000Source | 154,890,000Source | 139,390,000Source | 226,384,000Source | 169,535,000Source | 125,458,000Source | 211,750,000Source | 189,651,000Source | 139,482,000Source | 118,260,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 12,880,000Source | 10,571,000Source | 9,949,000Source | 11,553,000Source | 7,009,000Source | 13,985,000Source | 15,030,000Source | 9,717,000Source | 14,405,000Source | 15,329,000Source | 9,588,000Source | 3,611,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,971,000Source | 9,379,000Source | 7,394,000Source | 8,155,000Source | 6,770,000Source | 7,591,000Source | 8,337,000Source | 6,968,000Source | 7,783,000Source | 8,554,000Source | 6,785,000Source | 7,513,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 316,413,000Source | 293,918,000Source | 401,971,000Source | 295,734,000Source | 248,453,000Source | 391,192,000Source | 308,068,000Source | 235,330,000Source | 347,391,000Source | 319,674,000Source | 241,753,000Source | 130,138,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 37,000Source | 35,000Source | 37,000Source | 36,000Source | 35,000Source | 37,000Source | 35,000Source | 35,000Source | 37,000Source | 35,000Source | 35,000Source | 30,000Source |
| Additional Paid in CapitalUSD | 210,129,000Source | 216,103,000Source | 216,559,000Source | 213,788,000Source | 212,439,000Source | 212,795,000Source | 225,581,000Source | 207,995,000Source | 208,933,000Source | 221,002,000Source | 204,635,000Source | 137,058,000Source |
| Retained Earnings (Accumulated Deficit)USD | -163,150,000Source | -158,162,000Source | -201,396,000Source | -164,170,000Source | -153,942,000Source | -184,126,000Source | -169,165,000Source | -147,469,000Source | -156,524,000Source | -151,385,000Source | -133,904,000Source | -109,493,000Source |
| Stockholders' Equity Attributable to ParentUSD | 47,016,000Source | 57,976,000Source | 15,200,000Source | 49,654,000Source | 58,532,000Source | 28,706,000Source | 56,451,000Source | 60,561,000Source | 52,446,000Source | 69,652,000Source | 70,766,000Source | 27,595,000Source |
| Liabilities and EquityUSD | 363,074,000Source | 351,539,000Source | 416,816,000Source | 345,033,000Source | 306,630,000Source | 419,543,000Source | 364,164,000Source | 295,536,000Source | 399,482,000Source | 388,971,000Source | 312,164,000Source | 157,378,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 65,400,000Source | 95,005,000Source | 102,171,000Source | 248,884,000Source | 53,551,000Source | 91,439,000Source | 186,986,000Source | 41,753,000Source | 96,302,000Source | 91,343,000Source | 49,344,000Source | 18,632,000Source |
| Operating Lease, Liability, CurrentUSD | 859,000Source | 507,000Source | 944,000Source | 782,000Source | 767,000Source | 915,000Source | 611,000Source | 795,000Source | 887,000Source | 497,000Source | 806,000Source | 723,000Source |
| Accounts Payable, CurrentUSD | 18,993,000Source | — | 26,265,000Source | 23,415,000Source | — | 26,125,000Source | 37,095,000Source | — | 35,355,000Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 8,139,000Source | 9,500,000Source | 7,421,000Source | 8,366,000Source | 6,543,000Source | 7,666,000Source | 8,581,000Source | 6,716,000Source | 7,905,000Source | 8,792,000Source | 6,524,000Source | 7,332,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source | -355,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 53,734,000Source | — | — | 52,727,000Source | — | — | — | — | 20,147,000Source | 15,146,000Source | 779,000Source |
| Long-term DebtUSD | 347,239,000Source | 230,651,000Source | — | 250,620,000Source | 236,261,000Source | 300,000,000Source | 256,911,000Source | 243,443,000Source | 250,000,000Source | 262,737,000Source | 246,717,000Source | 151,773,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | 7,433,000Source | — | — | 8,681,000Source | 5,589,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,837,000Source | 4,556,000Source | 12,502,000Source | 17,619,000Source | 15,696,000Source | 7,974,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -9,831,000Source | -39,196,000Source | -5,010,000Source | 80,232,000Source | 30,344,000Source | 1,860,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,973,000Source | 14,000Source | 2,821,000Source | -165,000Source | 4,326,000Source | 2,324,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,992,000Source | 19,668,000Source | 43,864,000Source | -22,202,000Source | 3,840,000Source | 1,705,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -18,203,000Source | -212,000Source | -5,460,000Source | -33,164,000Source | -152,553,000Source | -1,743,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 194,000Source | 170,000Source | 887,000Source | 1,595,000Source | 1,460,000Source | 2,597,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 48,912,000Source | 23,000Source | -12,724,000Source | 28,528,000Source | 126,528,000Source | 54,141,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 21,717,000Source | 19,479,000Source | 25,680,000Source | -26,838,000Source | -22,185,000Source | 54,103,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 72,601,000Source | — | — | — | — | — | — | — | 96,270,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 10,960,000Source | 6,392,000Source | 18,718,000Source | 20,594,000Source | 18,887,000Source | 6,480,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 38,000Source | 93,000Source | 374,000Source | — | 75,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,270,000Source | 4,385,000Source | — | 875,000Source | — | 4,556,000Source | 12,502,000Source | 17,619,000Source | 15,696,000Source | 7,974,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 451,000Source | 1,275,000Source | 4,050,000Source | 4,205,000Source | 4,097,000Source | 782,000Source |
| Amortization of Intangible AssetsUSD | — | — | 4,224,000Source | 2,605,000Source | 5,527,000Source | 4,226,000Source | 5,129,000Source | 4,226,000Source | 16,991,000Source | 11,783,000Source | 10,082,000Source | 1,578,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | — | — | — | — | — | — | 4,358,000Source | — | — | — |
| Depreciation, Amortization and Accretion, NetUSD | — | — | 326,000Source | 351,000Source | — | 347,000Source | — | 312,000Source | 1,315,000Source | 1,269,000Source | 1,055,000Source | 1,253,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 168,000Source | 99,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | -253,000Source | — | 686,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | -3,171,000Source | 3,092,000Source | -2,914,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -13,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -7,750,000Source | — | — | — | — | — | -7,750,000Source | — | — | — |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | — | — | — | — | — | — | — | — | 5,259,000Source |
| GoodwillUSD | — | — | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source | 332,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | — | 380,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 20,000Source | 0Source | 0Source | 25,000Source | — | 3,771,000Source | 161,000Source | 701,000Source | 75,000Source |
| InterestExpenseNonoperatingUSD | — | — | 6,038,000Source | 5,525,000Source | 6,263,000Source | 6,408,000Source | 5,497,000Source | 6,548,000Source | 24,180,000Source | 22,786,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,020,000Source | -4,220,000Source | -17,270,000Source | 4,995,000Source | -27,602,000Source | -17,780,000Source | -5,139,000Source | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 1,020,000Source | -4,220,000Source | — | 4,995,000Source | — | -17,780,000Source | — | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Nonoperating Income (Expense)USD | — | — | -13,727,000Source | -5,521,000Source | — | -6,414,000Source | — | -6,548,000Source | -31,883,000Source | -26,142,000Source | -24,141,000Source | -15,930,000Source |
| Operating ExpensesUSD | — | — | 39,179,000Source | 35,918,000Source | 61,370,000Source | 36,103,000Source | 49,125,000Source | 43,539,000Source | 173,854,000Source | 141,547,000Source | 90,122,000Source | 61,293,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,232,000Source | 1,117,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 61,000Source | 4,000Source | 0Source | -6,000Source | — | — | 47,000Source | -185,000Source | -444,000Source | 102,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 22,655,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 25,000Source | 23,000Source | 467,000Source | 1,110,000Source | 379,000Source | 642,000Source |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 71,638,000Source | 49,257,000Source | 70,661,000Source | 63,742,000Source | 44,203,000Source | 47,831,000Source | 272,303,000Source | 199,614,000Source | 130,193,000Source | 88,595,000Source |
| Cost of RevenueUSD | — | — | 17,712,000Source | 12,018,000Source | 20,298,000Source | 16,230,000Source | 17,158,000Source | 15,524,000Source | 67,934,000Source | 49,245,000Source | 39,640,000Source | 25,383,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 35,856,000Source | 33,645,000Source | 53,298,000Source | 33,235,000Source | 43,230,000Source | 40,513,000Source | 152,914,000Source | 129,064,000Source | 83,090,000Source | 58,243,000Source |
| Operating Income (Loss)USD | — | — | 14,747,000Source | 1,321,000Source | -11,007,000Source | 11,409,000Source | -22,080,000Source | -11,232,000Source | 30,515,000Source | 8,822,000Source | 431,000Source | 1,919,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 61,000Source | 4,000Source | 0Source | -6,000Source | — | — | 47,000Source | -185,000Source | -444,000Source | 102,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 1,020,000Source | -4,200,000Source | -17,270,000Source | 4,995,000Source | -27,577,000Source | -17,780,000Source | -1,368,000Source | -17,320,000Source | -23,710,000Source | -14,011,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 20,000Source | 0Source | 0Source | 25,000Source | — | 3,771,000Source | 161,000Source | 701,000Source | 75,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,020,000Source | -4,220,000Source | -17,270,000Source | 4,995,000Source | -27,602,000Source | -17,780,000Source | -5,139,000Source | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.03Source | -0.12Source | -0.46Source | 0.14Source | -0.74Source | -0.5Source | -0.14Source | -0.49Source | -0.75Source | -0.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.03Source | -0.12Source | -0.46Source | 0.13Source | -0.74Source | -0.5Source | -0.14Source | -0.49Source | -0.75Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 37,145,440Source | 35,702,200Source | 37,350,401Source | 36,790,306Source | 37,231,321Source | 35,826,452Source | 36,760,461Source | 35,650,714Source | 32,616,777Source | 27,460,968Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 38,875,005Source | 35,702,200Source | 37,350,401Source | 38,853,855Source | 37,231,321Source | 35,826,452Source | 36,760,461Source | 35,650,714Source | 32,616,777Source | — |
| Interest Expense (non-operating)USD | — | — | 6,038,000Source | 5,525,000Source | 6,263,000Source | 6,408,000Source | 5,497,000Source | 6,548,000Source | 24,180,000Source | 22,786,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 4,224,000Source | 2,605,000Source | 5,527,000Source | 4,226,000Source | 5,129,000Source | 4,226,000Source | 16,991,000Source | 11,783,000Source | 10,082,000Source | 1,578,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,771,000Source | 161,000Source | 701,000Source | 75,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 455,000Source | 465,000Source | 1,915,000Source | 1,850,000Source | 1,530,000Source | 1,477,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | -3,171,000Source | 3,092,000Source | -2,914,000Source |
| Gross ProfitUSD | — | — | 53,926,000Source | 37,239,000Source | 50,363,000Source | 47,512,000Source | 27,045,000Source | 32,307,000Source | 204,369,000Source | 150,369,000Source | 90,553,000Source | 63,212,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 21,324,000Source | 7,244,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 1,020,000Source | -4,220,000Source | — | 4,995,000Source | — | -17,780,000Source | — | -17,481,000Source | -24,411,000Source | -14,086,000Source |
| Nonoperating Income (Expense)USD | — | — | -13,727,000Source | -5,521,000Source | — | -6,414,000Source | — | -6,548,000Source | -31,883,000Source | -26,142,000Source | -24,141,000Source | -15,930,000Source |
| Operating ExpensesUSD | — | — | 39,179,000Source | 35,918,000Source | 61,370,000Source | 36,103,000Source | 49,125,000Source | 43,539,000Source | 173,854,000Source | 141,547,000Source | 90,122,000Source | 61,293,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,232,000Source | 1,117,000Source |
| Research and Development ExpenseUSD | — | — | 3,323,000Source | 2,273,000Source | 8,072,000Source | 2,868,000Source | 5,895,000Source | 3,026,000Source | 20,940,000Source | 12,230,000Source | 6,652,000Source | 3,050,000Source |
Filing attachments
hrow-20261001xex991.htm · 8-K · 2026-10-05
Exhibit 99.1 Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise NASHVILLE, Tenn., October 5, 2026 - Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a glob…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Harrow Announces Second Quarter 2026 Financial Results Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure) VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially …
Read attachment ↗ex99-2.htm · 8-K · 2026-08-10
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules; the second half is about converting growing demand into revenue and profits. The balance of this Letter to Stockholders describes why I believe we are set up well - for not only the second half of 2026, but for many years to come, including the opportunity to achieve our ambitious company-…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease NASHVILLE, Tenn., August 6, 2026 - Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonis…
Read attachment ↗ex99-1.htm · SCHEDULE 13G/A · 2026-07-31
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 31, 2026, is by and among Opaleye Management Inc., Opaleye, L.P. and James Silverman (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Harrow, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13d-1(k) promulgat…
Read attachment ↗